MAGEA3 and melanoma: Then in the melanoma cohort treated with anti-CTLA4 and anti-PD1 (GSE91061), the melanoma cohort immunotherapeutically treated with the MAGE-A3 antigen (GSE35640), and the NSCLC cohort treated with nilumab (anti-PD-1 antibody) (GSE126044), we found that the low-risk group still showed better immune response, i.e., the high-risk group had less benefit for immunotherapy (Figures 10H-J).